ARL17B: A Potential Drug Target and Biomarker (G100506084)

Target Name: ARL17B

NCBI ID: G100506084

ARL17B

ARL17B: A Potential Drug Target and Biomarker

ARL17B, also known as ARL17, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and diverse functions have made it an attractive target for researchers to investigate, leading to a growing body of research that has shed light on its role in these conditions.

Structure and Function

ARL17B is a small non-coding RNA molecule that contains 24 amino acid residues. It belongs to the ARL17 family, which is characterized by a conserved catalytic core and a unique N-terminal region that contains a farnesylated cysteine residue. This cysteine residue is known to play a crucial role in the stability and activity of RNA molecules, and its farnesylation is a hallmark of the ARL17 family.

ARL17B has been shown to have various functions, including regulating gene expression, modulating cellular signaling pathways, and participating in cellular signaling cascades. One of its most well-studied functions is its role as a negative regulator of the AP-1 gene, which is a transcription factor that plays a central role in regulating gene expression.

ARL17B has been shown to regulate the activity of the AP-1 gene by binding to its N-terminal region and preventing the access of the transcription factor to the active site. This interaction between ARL17B and AP-1 has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis.

In addition to its role as a negative regulator of AP-1, ARL17B has also been shown to play a role in the regulation of other transcription factors, including p53, a well-known tumor suppressor gene. p53 is known to play a crucial role in regulating cellular stress responses and has been implicated in a wide range of diseases, including cancer.

ARL17B has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in a wide range of diseases, including cancer.

Drug Target Potential

The unique structure and functions of ARL17B have made it an attractive target for drug development. Several studies have shown that inhibiting the activity of ARL17B can lead to the inhibition of various cellular processes that are associated with the disease.

One of the most promising strategies for targeting ARL17B is the use of small molecules that can inhibit its activity as a negative regulator of AP-1 and p53. These small molecules can be found as natural products, such as plant or animal compounds, or as synthetic compounds, such as drugs.

Another approach for targeting ARL17B is the use of RNA interference (RNAi) technology. RNAi is a technique that uses small interfering RNA (siRNA) to knockdown the expression of specific genes in cells. By using RNAi to knockdown the expression of ARL17B, researchers can reduce the amount of ARL17B in the cell and potentially reduce its activity.

Biomarker Potential

The unique functions of ARL17B have also made it an attractive target for the development of biomarkers for various diseases. The regulation of ARL17B by AP-1 and p53 has been shown to play a role in the development and progression of various diseases, including cancer.

One of the most promising strategies for developing ARL17B as a biomarker is the use of its expression as a biomarker for cancer. Cancer is a leading cause of death worldwide, and there is a need for more effective methods for the early detection and treatment of cancer.

AR

Protein Name: ADP Ribosylation Factor Like GTPase 17B

Functions: GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus (By similarity)

The "ARL17B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL17B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets